Odefsey (Emtricitabine, Rilpivirine, and Tenofovir Alafenamide Fixed-dose Combination Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 20, 2017 Category: Drugs & Pharmacology Source Type: news
Scotland approves a controversial anti-HIV drug
The Scottish Medicines Consortium (SMC) has approved the pre-exposure prophylaxis (PrEP) treatment, which has the brand name Truvada.A trial of the drug in England will start in 2017-18. (Source: the Mail online | Health)
Source: the Mail online | Health - April 11, 2017 Category: Consumer Health News Source Type: news
NHS' anti-HIV drug PrEP approved in Scotland, UK
The Scottish Medicines Consortium (SMC), UK, has approved the supply of Emtricitabine / tenofovir disoproxil (Truvada) by the National Health Service (NHS) to prevent HIV in the nation. (Source: Drug Development Technology)
Source: Drug Development Technology - April 10, 2017 Category: Pharmaceuticals Source Type: news
South Africa: Men Soon to Get HIV Prevention Pill
[Bhekisisa] By June, the health department will know more about how to roll out Truvada nationally to men who have sex with men. (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - March 31, 2017 Category: Infectious Diseases Source Type: news
PrEP Is Making a Difference. Now Republicans Want to Make It Unaffordable
Evan J. Peterson learned about AIDS before he knew what “gay” meant. A child of the ‘80s, he recalls growing up in an age when he was constantly told that sex could kill him.
“Having to form a sexual identity in that era was a burden,” he says.
Now, Peterson takes Truvada, a pre-exposure prophylaxis (“PrEP”) that lowers his risk of contracting HIV by close to 99%. The once-a-day pill allows Peterson to say he’s negative with reasonable certainty, in addition to test results and the integrity of his sexual partners. “We have control of our own health,” he says. &ld...
Source: Healthy Living - The Huffington Post - March 8, 2017 Category: Consumer Health News Source Type: news
Stribild (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir DF) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 10, 2017 Category: Drugs & Pharmacology Source Type: news
Backed by strong numbers, Gilead takes to social media to market one-of-a-kind drug to prevent HIV
The success of the only FDA-approved drug to prevent infection of the AIDS virus — and the potential of reaching more people at risk of contracting HIV — is prompting Gilead Sciences Inc. to boost its direct-to-consumer marketing on Snapchat, Tumblr and other social media and dating sites.
It is a somewhat controversial shift in Foster City-based Gilead's strategy around th e marketing of the drug, called Truvada, for what is known as pre-exposure prophylaxis, or PrEP. Before PrEP won Food and… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 8, 2017 Category: Biotechnology Authors: Ron Leuty Source Type: news
Backed by strong numbers, Gilead takes to social media to market one-of-a-kind drug to prevent HIV
The success of the only FDA-approved drug to prevent infection of the AIDS virus — and the potential of reaching more people at risk of contracting HIV — is prompting Gilead Sciences Inc. to boost its direct-to-consumer marketing on Snapchat, Tumblr and other social media and dating sites.
It is a somewhat controversial shift in Foster City-based Gilead's strategy around th e marketing of the drug, called Truvada, for what is known as pre-exposure prophylaxis, or PrEP. Before PrEP won Food and… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 8, 2017 Category: American Health Authors: Ron Leuty Source Type: news
Is PrEP Failing To Reach Those At The Highest Risk Of Contracting HIV?
The use of Truvada as PrEP—pre-exposure prophylaxis to prevent HIV—is going gangbusters.
By the end of 2015, likely well over 80,000 U.S. residents had filled at least one prescription for the daily tablet. And given the steadily increasing rate of new prescriptions registered each quarter, the population of HIV-negative people who have at least tried PrEP has probably swelled considerably by now. This is fantastic news for the effort to stem the tide of HIV infections among men who have sex with men (MSM), whom data suggest make up the vast majority of PrEP users. While it’s still too early to determine ...
Source: Healthy Living - The Huffington Post - January 10, 2017 Category: Consumer Health News Source Type: news
CDC guidelines for HIV prevention regimen may not go far enough, study suggests
A new study from the UCLA Fielding School of Public Health suggests modifying federal health guidelines related to the use of pre-exposure prophylaxis to prevent HIV transmission because current standards could miss some people who should be on it.Pre-exposure prophylaxis, or PrEP, is a measure that has proven to be highly effective in preventing HIV transmission during unprotected sex. While not entirely foolproof, studies have shown taking daily doses of tenofovir disoproxil-emtricitabine, or Truvada, is 92 percent effective in preventing HIV infection when taken correctly and consistently.Since 2012, the U.S. Centers fo...
Source: UCLA Newsroom: Health Sciences - January 7, 2017 Category: Universities & Medical Training Source Type: news
NIAID initiates Phase III HPTN 083 trial of anti-HIV drug
The National Institute of Allergy and Infectious Diseases (NIAID) in the US has initiated the Phase III HPTN 083 trial of cabotegravir and truvada to treat men and transgender women with HIV. (Source: Drug Development Technology)
Source: Drug Development Technology - December 22, 2016 Category: Pharmaceuticals Source Type: news
Genvoya (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 20, 2016 Category: Drugs & Pharmacology Source Type: news
NIH launches first large trial of a long-acting injectable drug for HIV prevention
(NIH/National Institute of Allergy and Infectious Diseases) The first large-scale clinical trial of a long-acting injectable drug for HIV prevention began today. The study, sponsored by NIH, will examine whether a long-acting form of the investigational anti-HIV drug cabotegravir injected once every 8 weeks can safely protect men and transgender women from HIV infection at least as well as the anti-HIV medication Truvada taken daily as an oral tablet. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 20, 2016 Category: Infectious Diseases Source Type: news
HIV prevention trials network launches HPTN 083
(FHI360) The HIV Prevention Trials Network (HPTN) has launched a new study, HPTN 083, to evaluate whether injectable cabotegravir (CAB) can safely protect men who have sex with men (MSM) and transgender women (TGW) who have sex with men from acquiring HIV as well as daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC). If found to be safe and effective for HIV pre-exposure prophylaxis, also known as PrEP, injectable CAB may be easier for some people to adhere to than daily oral TDF/FTC. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 20, 2016 Category: Global & Universal Source Type: news
NHS to launch three-year anti-HIV PrEP trial
Truvada drug to be made available to 10,000 people at risk (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - December 4, 2016 Category: Pharmaceuticals Source Type: news
